Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1987 5
1988 6
1989 4
1990 3
1991 1
1992 5
1993 9
1994 11
1995 7
1996 13
1997 17
1998 11
1999 5
2000 6
2001 6
2002 1
2003 8
2004 1
2005 2
2006 4
2007 3
2008 10
2009 5
2010 3
2011 4
2012 5
2013 6
2014 2
2015 1
2016 2
2017 2
2018 5
2019 2
2020 1
2022 1
2023 1
2024 3
2025 5
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182 results

Results by year

Filters applied: . Clear all
Page 1
Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial.
Lehr T, Meiser P, Selzer D, Rixecker T, Holzer F, Mösges R, Smola S, Bals R; CONTAIN Study Group. Lehr T, et al. JAMA Intern Med. 2025 Nov 1;185(11):1309-1317. doi: 10.1001/jamainternmed.2025.4283. JAMA Intern Med. 2025. PMID: 40892398 Free PMC article. Clinical Trial.
CONCLUSIONS AND RELEVANCE: In this single-center trial, azelastine nasal spray was associated with reduced risk of SARS-CoV-2 respiratory infections. These findings support the potential of azelastine as a safe prophylactic approach warranting confirmation in larger …
CONCLUSIONS AND RELEVANCE: In this single-center trial, azelastine nasal spray was associated with reduced risk of SARS-CoV-2 respira …
Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients.
Klussmann JP, Grosheva M, Meiser P, Lehmann C, Nagy E, Szijártó V, Nagy G, Konrat R, Flegel M, Holzer F, Groß D, Steinmetz C, Scherer B, Gruell H, Schlotz M, Klein F, de Aragão PA, Morr H, Al Saleh H, Bilstein A, Russo B, Müller-Scholtz S, Acikel C, Sahin H, Werkhäuser N, Allekotte S, Mösges R. Klussmann JP, et al. Sci Rep. 2023 Apr 26;13(1):6839. doi: 10.1038/s41598-023-32546-z. Sci Rep. 2023. PMID: 37100830 Free PMC article. Clinical Trial.
Ninety SARS-CoV-2 positive patients were randomized into 3 groups receiving placebo, 0.02% or 0.1% azelastine nasal spray for 11 days, during which viral loads were assessed by quantitative PCR. ...Comparable numbers of adverse events occurred in all treatment groups with …
Ninety SARS-CoV-2 positive patients were randomized into 3 groups receiving placebo, 0.02% or 0.1% azelastine nasal spray for 11 days …
Azelastine Nasal Spray in Non-Hospitalized Subjects with Mild COVID-19 Infection: A Randomized Placebo-Controlled, Parallel-Group, Multicentric, Phase II Clinical Trial.
Meiser P, Flegel M, Holzer F, Groß D, Steinmetz C, Scherer B, Jain R, Carvin-Ii Study Group. Meiser P, et al. Viruses. 2024 Dec 13;16(12):1914. doi: 10.3390/v16121914. Viruses. 2024. PMID: 39772221 Free PMC article. Clinical Trial.
A total of 39 (32.0%) subjects in the azelastine 0.1% treatment group and 40 (31.0%) subjects in the placebo group reported 48 and 51 adverse events, respectively. It is therefore concluded that azelastine 0.1% nasal spray is an efficacious, safe, and well-tolerated …
A total of 39 (32.0%) subjects in the azelastine 0.1% treatment group and 40 (31.0%) subjects in the placebo group reported 48 and 51 …
A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial.
Esmaeilzadeh H, Far NM, Nabavizadeh SH, Babaeian M, Hadipour M, Alyasin S. Esmaeilzadeh H, et al. Am J Rhinol Allergy. 2022 Sep;36(5):559-567. doi: 10.1177/19458924221086268. Epub 2022 Mar 18. Am J Rhinol Allergy. 2022. PMID: 35300506 Clinical Trial.

Three months after treatment, the mean decrease of SNOT-22 in the Azelastine group was statistically significant compared to both Montelukast (P-value < 0.001) and control groups (P-value < 0.001). ...CONCLUSION: Based on our findings, we recommend Azelastine

…
Three months after treatment, the mean decrease of SNOT-22 in the Azelastine group was statistically significant compared to both Mon …
Azelastine tablets in the treatment of chronic idiopathic urticaria. Phase iii, randomised, double-blind, placebo and active controlled multicentric clinical trial.
Camarasa JM, Aliaga A, Fernández-Vozmediano JM, Fonseca E, Iglesias L, Tagarro I. Camarasa JM, et al. Skin Pharmacol Appl Skin Physiol. 2001 Mar-Apr;14(2):77-86. doi: 10.1159/000056337. Skin Pharmacol Appl Skin Physiol. 2001. PMID: 11316966 Clinical Trial.
This trial was designed to study the efficacy and tolerability of azelastine in controlling symptoms of chronic idiopathic urticaria, using ebastine as validation group. ...Global assessments of efficacy and tolerability performed by the investigators, also favoured aze …
This trial was designed to study the efficacy and tolerability of azelastine in controlling symptoms of chronic idiopathic urticaria, …
The efficiency of azelastine hydrochloride and fluticasone propionate nasal spray to improve PAP adherence in patients with obstructive sleep apnea.
Wongchan R, Tepwimonpetkun C, Kitsongsermthon J, Sapankaew T, Yotsombut K, Chittiwan W. Wongchan R, et al. Sci Rep. 2025 Apr 26;15(1):14601. doi: 10.1038/s41598-025-99548-x. Sci Rep. 2025. PMID: 40287492 Free PMC article. Clinical Trial.
This study aimed to assess the combined effectiveness of INS (fluticasone propionate) and intranasal antihistamines (azelastine hydrochloride) in enhancing CPAP adherence and mitigating CPAP-induced rhinitis symptoms in OSA patients. ...Although these drugs did not signifi …
This study aimed to assess the combined effectiveness of INS (fluticasone propionate) and intranasal antihistamines (azelastine hydro …
Azelastine reduces allergen-induced nasal response: a clinical and rhinomanometric assessment.
Lurie A, Saudubray F, Eychenne JL, Venot A, de Lauture D, Dessanges JF, Lockhart A, Strauch G. Lurie A, et al. Eur J Clin Pharmacol. 1992;42(2):213-6. doi: 10.1007/BF00278487. Eur J Clin Pharmacol. 1992. PMID: 1352247 Clinical Trial.
The effect of azelastine 2 mg b.d. p.o. for 10 days on grass pollen-induced nasal responses in 16 patients with grass pollen allergic rhinitis has been assessed. ...The visual analogue scores were similar before and after azelastine as well as before and after the p …
The effect of azelastine 2 mg b.d. p.o. for 10 days on grass pollen-induced nasal responses in 16 patients with grass pollen allergic …
Comparison of azelastine and chlorpheniramine in the treatment of mastocytosis.
Friedman BS, Santiago ML, Berkebile C, Metcalfe DD. Friedman BS, et al. J Allergy Clin Immunol. 1993 Oct;92(4):520-6. doi: 10.1016/0091-6749(93)90076-r. J Allergy Clin Immunol. 1993. PMID: 8104966 Clinical Trial.
RESULTS: Subjects' mean wheal area responses provoked by histamine or morphine sulfate were significantly lowered by azelastine when compared with chlorpheniramine. Plasma histamine levels in subjects receiving azelastine or chlorpheniramine were not significantly d …
RESULTS: Subjects' mean wheal area responses provoked by histamine or morphine sulfate were significantly lowered by azelastine when …
Nasal saline irrigation with azelastine-fluticasone nasal spray in moderate-to-severe persistent allergic rhinitis: a randomized controlled trial.
Li S, Xu R, Yu S, Wang M, Fan J, Chen M, Gong X, Gu Q, Chen F, Jin L, Geng C, Yan M, Qiu C, Lu M, Cheng L. Li S, et al. Front Allergy. 2025 Oct 13;6:1622510. doi: 10.3389/falgy.2025.1622510. eCollection 2025. Front Allergy. 2025. PMID: 41158297 Free PMC article. Clinical Trial.
The experimental group received nasal saline irrigation combined with azelastine-fluticasone (Aze-Flu) nasal spray, and the control group was treated with azelastine nasal spray and fluticasone nasal spray. ...
The experimental group received nasal saline irrigation combined with azelastine-fluticasone (Aze-Flu) nasal spray, and the control g …
Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity.
Ciprandi G, Buscaglia S, Catrullo A, Pesce G, Fiorino N, Montagna P, Bagnasco M, Canonica GW. Ciprandi G, et al. Clin Exp Allergy. 1997 Feb;27(2):182-91. Clin Exp Allergy. 1997. PMID: 9061218 Clinical Trial.
We have recently demonstrated that nasal azelastine inhibits the clinical and inflammatory events following nasal allergen challenge. ...The former investigated the onset of effect of a single dose of azelastine eye drops administered 20 min after clinical response …
We have recently demonstrated that nasal azelastine inhibits the clinical and inflammatory events following nasal allergen challenge. …
182 results